Madia Lozupone, Giuseppe Berardino, Anita Mollica, Rodolfo Sardone, Vittorio Dibello, Roberta Zupo, Luisa Lampignano, Fabio Castellana, Ilaria Bortone, Roberta Stallone, Antonio Daniele, Mario Altamura, Antonello Bellomo, Vincenzo Solfrizzi, Francesco Panza
INTRODUCTION: For Alzheimer's disease (AD) treatment, US FDA granted accelerated approval for aducanumab due to its amyloid-β (Aβ)-lowering effects, notwithstanding the reported poor correlation between amyloid plaque reduction and clinical change for this drug. The diversification of drug targets appears to be the future of the AD field and from this perspective, drugs modulating microglia dysfunction and combination treatment regimens offer some promise. AREAS COVERED: The aim of the present article was to provide a comprehensive review of ALZT-OP1 (cromolyn sodium plus ibuprofen), an experimental combination treatment regimen for AD, discussing their mechanisms of action targeting Aβ and neuroinflammation, examining the role of microglia in AD and offering our own insights on the role of present and alternative approaches directed toward neuroinflammation...
August 2022: Expert Opinion on Investigational Drugs